6-Thioguanine pharmacokinetics

LePage GA, Whitecar JP. Pharmacology of 6-thioguaninc in man. Cancer Res 1971 31 1627-1631. Konits PH, Egorin MJ, Van Echo DA et al. Phase II evaluation and plasma pharmacokinetics of high-dose intravenous 6-thioguanine in patients with colorectal carcinoma. Cancer Chemother Pharmacol 1982 8 199-203. [Pg.196]

Erb N, Harms DO, Janka-Schaub G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine. Cancer Chemother Pharmacol 1998 42 266-272. [Pg.196]

Pharmacokinetics Predominantly renally excreted Thioguanine oral only, eliminated Cytarabine extensive hepatic... [Pg.146]

Lancaster DL, Ratel N, Lennard L, Lilleyman JS. 6-Thioguanine in children with acute lymphoblastic leukemia Influence of food on parent drug pharmacokinetics and 6-thioquanine nucleotide concentrations. Br. J Clin Rharmacol 2001 51 531-539. [Pg.1641]

Pharmacokinetics Mercaptopurine and thioguanine have low oral bioavailability due to first-pass metabolism by hepatic enzymes. The metabolism of 6-MP by xanthine oxidase is inhibited by allopurinol. [Pg.481]

Drug-drug interactious Methotrexate The pharmacokinetic interaction between methotrexate and mercaptopurine has been studied in 20 children with acute lymphoblastic leukemia [154 ]. High-dose methotrexate (5 g/m over 24 hours) produced a rapid reduction in erythrocyte concentrations of thioguanine within 24 hours, and... [Pg.830]

Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...